Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lutetium Lu 177 dotatate + sunitinib malate
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous, Oral
01
Overview
lutetium Lu 177 dotatate + sunitinib malate is a combination therapy being investigated for the treatment of metastatic or unresectable pancreatic neuroendocrine tumors (pNETs). The combination pairs **lutetium Lu 177 dotatate** (Lutathera), a peptide receptor radionuclide therapy (PRRT), with **sunitinib malate** (Sutent), a multi-targeted receptor tyrosine kinase inhibitor. Lutetium Lu 177 dotatate consists of a somatostatin analogue (dotatate) linked to the beta-emitting radioisotope lutetium-177, which targets and destroys cells expressing somatostatin receptor type 2 (SSTR2). Sunitinib malate complements this by inhibiting several kinases involved in tumor growth and angiogenesis, including vascular endothelial growth factor receptors (VEGFR) and platelet-derived growth factor receptors (PDGFR). This combination is currently being evaluated in a Phase I trial (NCT05687123) sponsored by the National Cancer Institute (NCI) to determine safety and potential synergistic effects in patients with somatostatin receptor-positive pNETs.
- Brand names
- LutatheraSutent
- Other names
- 177Lu-DOTATATE + sunitiniblutetium Lu 177 dotatate and sunitinib malate
02
Targets
PDGFRB (Platelet-derived growth factor receptor beta)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)PDGFRA (Platelet-derived growth factor receptor alpha)CSF1R (Macrophage colony-stimulating factor receptor)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR3 (Vascular endothelial growth factor receptor 3)SSTR2 (Somatostatin receptor type 2)RET (Rearranged during transfection receptor tyrosine kinase)FLT3 (Fms related receptor tyrosine kinase 3)
Beyond the preview
Go deeper on lutetium Lu 177 dotatate + sunitinib malate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lutetium Lu 177 dotatate + sunitinib malate.